Pharmaceutical Policy Experts™

divider

Founders

jointMadeline Carpinelli Wallack and Suzanne Herzog forged their professional partnership in 2004 at the Office of Inspector General (OIG) for the Department of Health and Human Services.  While at the OIG, they specialized in the review of federal discount programs and led five evaluations focused on 340B and Medicaid. They assisted in the creation of the OIG’s 2002 “Compliance Program Guidance for Pharmaceutical Manufacturers,” won several awards for their studies, and provided subject matter expertise to the Office of Counsel to the Inspector General and the Department of Justice on drug pricing practices for federal investigations.

In 2009, they identified a need for expert education and guidance surrounding the 340B program and founded Rx|X Consulting.  They have proudly worked with hospitals, health centers, and grantees of all sizes and across the country.  They have assisted Apexus as subject matter experts on a number of projects, including the creation of the Advanced Certification Program.  In addition, they served as contracted senior policy consultants for the HRSA Pharmacy Services Support Center (PSSC) at the American Pharmacists Association between 2011-2014 where they created policy briefs for OPA, developed tools and provided technical support for entities, and participated in the creation  of the HRSA audit process.

Dr. Wallack and Ms. Herzog have dedicated their careers to 340B program and policy work and specialize on comprehensive compliance assessments. This also includes independent reviews, HRSA audit preparation and corrective action response, manufacturer audit readiness, and self-disclosures/dispute resolution.

Dr. Madeline Wallack

MCW_3449_ppDr. Wallack has been engaged in the analysis of public policy and economics of the pharmaceutical marketplace since 1999. The drive behind Rx|X comes from her passion for translating the complexities of 340B into robust programs understood by the teams operating the program as well as the C-suite.

She has had a notable presence in the ongoing dialogue of pharmaceutical policy, as demonstrated by her numerous speaking engagements at national 340B/Medicaid conferences. Dr. Wallack also had the honor of testifying before the Joint Economic Committee in Washington, DC, at the invitation of Senator Amy Klobuchar (D-MN) on the topic of “Extraordinary Drug Price Increases,” in July 2008. She has also supported 340B-related litigation, through data analysis, document review, and serving as an expert witness. She has also worked on a number of Department of Justice investigations on drug pricing and safety matters.

She was previously with the University of Minnesota’s Pharmaceutical Research in Management and Economics (PRIME) Institute in the College of Pharmacy.

Dr. Wallack has her M.S. and Ph.D. in Social and Administrative Pharmacy from the University of Minnesota’s College of Pharmacy. She has her Bachelor of Arts in Political Science and English Literature from Saint Mary’s College in Notre Dame, IN. Dr. Wallack resides in Minneapolis, MN, with her husband and three children.

Ms. Suzanne Herzog

Ms. Herzog has been engaged with 340B policy matters, both in the public and private sectors, since 2002. Ms. Herzog also got her formative training on 340B and Medicaid with the OIG before moving on to Rx|X in 2009.  Among Ms. Herzog’s contributions to 340B audits and strategic planning, her passion for data analytics is the power behind Rx|X’s business and compliance intelligence offerings.  Her ability to review massive data sets to detect data disconnects, IT feed inaccuracies, or other covert issues is truly a mix of art and science. SH_3224_pp

Ms. Herzog received her undergraduate degrees in Economics and Political Science summa cum laude from the University of Maryland, and her master of public policy (MPP) from the University of Chicago, where she was selected as a McCormick Tribune Fellow. Ms. Herzog resides in Morristown, NJ with her husband and four children.